Literature DB >> 9670968

T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas.

W Böhm1, S Thoma, F Leithäuser, P Möller, R Schirmbeck, J Reimann.   

Abstract

The murine melanoma cell line B16.F10 (H-2b) was used to study specific T cell responses that reject tumors. Stable B16 transfectants were established that express viral Ags, either the hepatitis B surface Ag (HBsAg) or the large tumor Ag (T-Ag) of SV40. B16 cells and their transfected sublines were CD40+ CD44+ but expressed no (or low levels of the) costimulator molecules CD154 (CD40L), CD48, CD54, CD80, and CD86. Surface expression of MHC class I (Kb, Db) and class II (I-Ab) molecules by B16 cells was low, but strikingly up-regulated by IFN-gamma. CD95 (Fas) and CD95 ligand (CD95L (FasL)) were "spontaneously" expressed by B16 cells growing in vitro in serum-free medium; these markers were strikingly up-regulated by IFN-gamma. B16 cells coexpressing CD95 and CD95L were irreversibly programmed for apoptosis. In vitro, noninduced B16 transfectants stimulated a specific IFN-gamma release response, but no cytolytic response (in a 4-h assay) in MHC class I-restricted CTL; in contrast, IFN-gamma-induced B16 targets were efficiently and specifically lysed by CTL. In vivo, B16 transfectants were specifically rejected by DNA-vaccinated syngeneic hosts through a T-dependent immune effector mechanism. The tumors showed evidence of massive apoptosis in vivo during the rejection process. The data suggest that CTL-derived IFN-gamma enhances an intrinsic suicide mechanism of these tumor cells in addition to facilitating lytic interactions of effectors with tumor targets.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9670968

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  47 in total

1.  Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant.

Authors:  Willem W Overwijk; Karin E de Visser; Felicia H Tirion; Laurina A de Jong; Thijs W H Pols; Yme U van der Velden; Jasper G van den Boorn; Anna M Keller; Wim A Buurman; Marc R Theoret; Bianca Blom; Nicholas P Restifo; Ada M Kruisbeek; Robert A Kastelein; John B A G Haanen
Journal:  J Immunol       Date:  2006-05-01       Impact factor: 5.422

2.  Type I Interferons are essential for the efficacy of replicase-based DNA vaccines.

Authors:  Wolfgang W Leitner; Elke S Bergmann-Leitner; Leroy N Hwang; Nicholas P Restifo
Journal:  Vaccine       Date:  2006-05-06       Impact factor: 3.641

3.  Mouse model for pre-clinical study of human cancer immunotherapy.

Authors:  Zhiya Ya; Yared Hailemichael; Willem Overwijk; Nicholas P Restifo
Journal:  Curr Protoc Immunol       Date:  2015-02-02

4.  Regulation of local and metastatic host-mediated anti-tumour mechanisms by L-selectin and intercellular adhesion molecule-1.

Authors:  M Yamada; K Yanaba; M Hasegawa; Y Matsushita; M Horikawa; K Komura; T Matsushita; A Kawasuji; T Fujita; K Takehara; D A Steeber; T F Tedder; S Sato
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

5.  B16 as a mouse model for human melanoma.

Authors:  W W Overwijk; N P Restifo
Journal:  Curr Protoc Immunol       Date:  2001-05

6.  Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination.

Authors:  Christopher A Klebanoff; Zhiya Yu; Leroy N Hwang; Douglas C Palmer; Luca Gattinoni; Nicholas P Restifo
Journal:  Blood       Date:  2009-06-26       Impact factor: 22.113

7.  Tumor-specific IL-9-producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers.

Authors:  Yong Lu; Bangxing Hong; Haiyan Li; Yuhuan Zheng; Mingjun Zhang; Siqing Wang; Jianfei Qian; Qing Yi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

8.  Paradoxical effects of IFN-gamma in graft-versus-host disease reflect promotion of lymphohematopoietic graft-versus-host reactions and inhibition of epithelial tissue injury.

Authors:  Hui Wang; Wannee Asavaroengchai; Beow Yong Yeap; Min-Guang Wang; Shumei Wang; Megan Sykes; Yong-Guang Yang
Journal:  Blood       Date:  2009-02-10       Impact factor: 22.113

9.  Tumor-specific Th17-polarized cells eradicate large established melanoma.

Authors:  Pawel Muranski; Andrea Boni; Paul A Antony; Lydie Cassard; Kari R Irvine; Andrew Kaiser; Chrystal M Paulos; Douglas C Palmer; Christopher E Touloukian; Krzysztof Ptak; Luca Gattinoni; Claudia Wrzesinski; Christian S Hinrichs; Keith W Kerstann; Lionel Feigenbaum; Chi-Chao Chan; Nicholas P Restifo
Journal:  Blood       Date:  2008-03-19       Impact factor: 22.113

10.  The innate immune system recognizes and regulates major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells.

Authors:  Bent Rubin; Joëlle Riond; Laetitia Courtiade; Nicolas Roullet; Jean-Edouard Gairin
Journal:  Cancer Immun       Date:  2008-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.